Glenmark Pharmaceuticals Limited
GLENMARK
주식 순위
#2717
Glenmark Pharmaceuticals Limited, including its associated entities, is a... Glenmark Pharmaceuticals Limited, including its associated entities, is a global pharmaceutical company specializing in the research, development, production, and marketing of medicinal products. Its operational reach spans India, North America, Latin America, Europe, and other international regions. The company's diverse offerings comprise both branded and generic drug formulations, with a strategic emphasis on therapeutic areas such as dermatology, respiratory conditions, and oncology. Additionally, Glenmark manufactures and supplies a variety of active pharmaceutical ingredients. The company's robust product pipeline includes several investigational therapies. Among its clinical-stage assets are ISB 830 (telazorlimab), an OX40 antagonist monoclonal antibody currently in Phase 2b trials for atopic dermatitis; ISB 1302, a HER2 x CD3 bispecific antibody undergoing Phase 1/2 studies for metastatic HER2-positive breast cancer; and ISB 1342, a CD38 x CD3 bispecific antibody in Phase 1 development for relapsed/refractory multiple myeloma. In its preclinical pipeline, Glenmark is advancing ISB 880 for anti-inflammatory applications; the T-cell engagers ISB 1908 and ISB 1909 for oncology indications; ISB 1442, an innate immune engager also targeting oncology; and GRC 39815, a retinoid-related orphan receptor gamma inhibitor aimed at treating chronic obstructive pulmonary disorder (COPD). Among its commercially available products is Ryaltris nasal spray, prescribed for allergic rhinitis. Founded in 1977, Glenmark Pharmaceuticals Limited is headquartered in Mumbai, India.
주가
$24.69
마지막 동기화: 2026-10-16
시가총액
$6.97B
변동 (1일)
-0.60%
변동 (1년)
16.71%
국가
IN
거래 Glenmark Pharmaceuticals Limited (GLENMARK)
카테고리
Healthcare
Glenmark Pharmaceuticals Limited (GLENMARK)의 영업이익률
October 2026 기준 영업이익률 TTM: 20.24%
Glenmark Pharmaceuticals Limited의 최신 재무 보고서와 주가에 따르면 현재 영업이익률 (TTM)은 20.24%입니다. 2024년 말 기준 영업이익률은 26.84%였습니다.
Glenmark Pharmaceuticals Limited의 영업이익률 기록 (2004 ~ 2026)
매년 말 영업이익률
| 연도 | 영업이익률 | 변화 |
|---|---|---|
| 2026 (TTM) | 20.24% | -35.36% |
| 2025 | 31.31% | 16.65% |
| 2024 | 26.84% | 182.23% |
| 2023 | 9.51% | -37.84% |
| 2022 | 15.30% | -0.71% |
| 2021 | 15.41% | 28.10% |
| 2020 | 12.03% | -26.56% |
| 2019 | 16.38% | 9.05% |
| 2018 | 15.02% | -10.01% |
| 2017 | 16.69% | 6.51% |
| 2016 | 15.67% | 30.47% |
| 2015 | 12.01% | -19.07% |
| 2014 | 14.84% | -17.09% |
| 2013 | 17.90% | 15.04% |
| 2012 | 15.56% | -28.10% |
| 2011 | 21.64% | -1.23% |
| 2010 | 21.91% | -11.90% |
| 2009 | 24.87% | -29.77% |
| 2008 | 35.41% | 22.65% |
| 2007 | 28.87% | 95.20% |
| 2006 | 14.79% | -28.89% |
| 2005 | 20.80% | 53.96% |
| 2004 | 13.51% | 0.00% |
유사 기업 또는 경쟁사의 영업이익률
| 회사 | 영업이익률 | 영업이익률 차이 | 국가 |
|---|---|---|---|
| 0.00% | - |
DE
|
|
| 0.00% | - |
DE
|
|
| 0.00% | - |
JP
|
|
| 0.00% | - |
CH
|
|
| 22.93% | -98.87% |
IN
|
회사의 영업이익률이란?
영업이익률은 회사의 수익성을 평가하는 핵심 지표입니다. 높은 영업이익률은 일반적으로 긍정적으로 간주되며, 이는 회사가 제품이나 서비스를 생산 비용보다 훨씬 높은 가격에 판매할 수 있음을 보여줍니다. 영업이익률은 회사의 수익을 매출로 나누어 계산합니다.